COPD und Begleiterkrankungen

R. Dierkesmann; A. Gillissen; T. Köhnlein; J. Lorenz; H. Magnussen; H. Morr; M. Pfeifer; G. Schultze-Werninghaus; G. Steinkamp; C. Taube; H. Teschler; C. Vogelmeier; H. Worth

doi:10.1055/s-0029-1214943

Pneumologie 2009; 63(9): 526-537
DOI: 10.1055/s-0029-1214943

Übersicht

COPD und Begleiterkrankungen

Ergebnisse des Expertentreffens Luftschlösser 2008
Tremsbüttel, 28. – 29. November 2008
Sponsor: Boehringer Ingelheim Pharma GmbH & Co KGCOPD and Concomitant DiseasesR. Dierkesmann¹ , A. Gillissen² , T. Köhnlein³ , J. Lorenz⁴ , H. Magnussen⁵ , H. Morr⁶ , M. Pfeifer⁷ , G. Schultze-Werninghaus⁸ , G. Steinkamp⁹ , C. Taube¹⁰ , H. Teschler¹¹ , C. Vogelmeier¹² , H. Worth¹³

¹Ehem. Direktor der Klinik Schillerhöhe, Gerlingen/Stuttgart
²Robert-Koch-Klinik, Thoraxzentrum des Klinikums St. Georg, Leipzig
³Abt. Pneumologie, Medizinische Hochschule Hannover
⁴Klinik für Pneumologie und Intensivmedizin, Klinikum Lüdenscheid
⁵Krankenhaus Großhansdorf, Zentrum für Pneumologie und Thoraxchirurgie, Großhansdorf, Lehrstuhl für Innere Medizin-Pneumologie, Großhansdorf, Universität zu Lübeck
⁶Pneumologische Klinik Waldhof Elgershausen, Greifenstein/Hessen
⁷Klinik Donaustauf, Universität Regensburg
⁸Berufsgenossenschaftliches Universitätsklinikum Bergmannsheil GmbH, Medizinische Klinik III – Pneumologie, Allergologie, Schlaf- und Beatmungsmedizin, Bochum
⁹Medizinisch-wissenschaftliches Publizieren, Hannover
¹⁰III. Med. Klinik, Johannes Gutenberg-Universität Mainz
¹¹Ruhrlandklinik Essen
¹²Klinik für Innere Medizin mit Schwerpunkt Pneumologie, Universitätsklinikum Gießen und Marburg, Standort Marburg
¹³Medizinische Klinik I, Klinikum Fürth

Abstract

Full Text

References

Literatur

1 Calverley P M, Rennard S I. What have we learned from large drug treatment trials in COPD?. Lancet. 2007; 370 774-785
2 Sin D D, Anthonisen N R, Soriano J B, Agusti A G. Mortality in COPD: Role of comorbidities. Eur Respir J. 2006; 28 1245-1257
3 Calverley P, Pauwels R, Vestbo J. et al . Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet. 2003; 361 449-456
4 Calverley P M, Anderson J A, Celli B. et al . Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med. 2007; 356 775-789
5 Jones P W, Agusti A G. Outcomes and markers in the assessment of chronic obstructive pulmonary disease. Eur Respir J. 2006; 27 822-832
6 Fletcher C, Peto R. The natural history of chronic airflow obstruction. Br Med J. 1977; 1 1645-1648
7 Casanova C, Cote C, de Torres J P. et al . Inspiratory-to-total lung capacity ratio predicts mortality in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2005; 171 591-597
8 Soler-Cataluna J J, Martinez-Garcia M A, Roman S P. et al . Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax. 2005; 60 925-931
9 Hogg J C, Chu F S, Tan W C. et al . Survival after lung volume reduction in chronic obstructive pulmonary disease: insights from small airway pathology. Am J Respir Crit Care Med. 2007; 176 454-459
10 Pinto-Plata V M, Cote C, Cabral H. et al . The 6-min walk distance: change over time and value as a predictor of survival in severe COPD. Eur Respir J. 2004; 23 28-33
11 Casanova C, Cote C, Marin J M. et al . Distance and oxygen desaturation during the 6-min walk test as predictors of long-term mortality in patients with COPD. Chest. 2008; 134 746-752
12 Martinez F J, Foster G, Curtis J L. et al . Predictors of mortality in patients with emphysema and severe airflow obstruction. Am J Respir Crit Care Med. 2006; 173 1326-1334
13 Celli B R, Cote C G, Marin J M. et al . The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med. 2004; 350 1005-1012
14 Cote C G, Pinto-Plata V M, Marin J M. et al . The modified BODE index: validation with mortality in COPD. Eur Respir J. 2008; 32 1269-1274
15 Minai O A, Benditt J, Martinez F J. Natural history of emphysema. Proc Am Thorac Soc. 2008; 5 468-474
16 Dirksen A, Piitulainen E, Parr D G. et al . Exploring the role of CT densitometry: a randomised study of augmentation therapy in alpha-1 antitrypsin deficiency. Eur Respir J. 2009; 33 1345-1353
17 Dawkins P A, Dawkins C L, Wood A M. et al . Rate of progression of lung function impairment in alpha1-antitrypsin deficiency. Eur Respir J. 2009; 33 1338-1344
18 Anthonisen N R, Connett J E, Kiley J P. et al . Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The Lung Health Study. JAMA. 1994; 272 1497-1505
19 Scanlon P D, Connett J E, Waller L A. et al . Smoking cessation and lung function in mild-to-moderate chronic obstructive pulmonary disease. The Lung Health Study. Am J Respir Crit Care Med. 2000; 161 381-390
20 Simmons M S, Connett J E, Nides M A. et al . Smoking reduction and the rate of decline in FEV(1): results from the Lung Health Study. Eur Respir J. 2005; 25 1011-1017
21 Godtfredsen N S, Lam T H, Hansel T T. et al . COPD-related morbidity and mortality after smoking cessation: status of the evidence. Eur Respir J. 2008; 32 844-853
22 Nakanishi N, Nakamura K, Matsuo Y. et al . Cigarette smoking and risk for impaired fasting glucose and type 2 diabetes in middle-aged Japanese men. Ann Intern Med. 2000; 133 183-191
23 Baker E H, Janaway C H, Philips B J. et al . Hyperglycaemia is associated with poor outcomes in patients admitted to hospital with acute exacerbations of chronic obstructive pulmonary disease. Thorax. 2006; 61 284-289
24 Davis W A, Knuiman M, Kendall P. et al . Glycemic exposure is associated with reduced pulmonary function in type 2 diabetes: the Fremantle Diabetes Study. Diabetes Care. 2004; 27 752-757
25 Baik I, Kim J, Abbott R D. et al . Association of snoring with chronic bronchitis. Arch Intern Med. 2008; 168 167-173
26 McNicholas W T, FitzGerald M X. Nocturnal deaths among patients with chronic bronchitis and emphysema. Br Med J (Clin Res Ed). 1984; 289 878
27 Ip M S, Lam B, Ng M M. et al . Obstructive sleep apnea is independently associated with insulin resistance. Am J Respir Crit Care Med. 2002; 165 670-676
28 Punjabi N M, Shahar E, Redline S. et al . Sleep-disordered breathing, glucose intolerance, and insulin resistance: the Sleep Heart Health Study. Am J Epidemiol. 2004; 160 521-530
29 Vgontzas A N. Does obesity play a major role in the pathogenesis of sleep apnoea and its associated manifestations via inflammation, visceral adiposity, and insulin resistance?. Arch Physiol Biochem. 2008; 114 211-223
30 Poulain M, Doucet M, Drapeau V. et al . Metabolic and inflammatory profile in obese patients with chronic obstructive pulmonary disease. Chron Respir Dis. 2008; 5 35-41
31 Mora S, Cook N, Buring J E. et al . Physical activity and reduced risk of cardiovascular events: potential mediating mechanisms. Circulation. 2007; 116 2110-2118
32 Garcia-Aymerich J, Lange P, Benet M. et al . Regular physical activity reduces hospital admission and mortality in chronic obstructive pulmonary disease: a population based cohort study. Thorax. 2006; 61 772-778
33 Garcia-Aymerich J, Lange P, Benet M. et al . Regular physical activity modifies smoking-related lung function decline and reduces risk of chronic obstructive pulmonary disease: a population-based cohort study. Am J Respir Crit Care Med. 2007; 175 458-463
34 Ainsworth B E, Haskell W L, Whitt M C. et al . Compendium of physical activities: an update of activity codes and MET intensities. Med Sci Sports Exerc. 2000; 32 498-504
35 Watz H, Waschki B, Meyer T, Magnussen H. Physical activity in patients with chronic obstructive pulmonary disease. Eur Respir J. 2009; 33 262-272
36 Watz H, Waschki B, Boehme C. et al . Extrapulmonary effects of chronic obstructive pulmonary disease on physical activity: a cross-sectional study. Am J Respir Crit Care Med. 2008; 177 743-751
37 Langer D. Physical activities in lung transplant candidates. Eur Respir J. 2006; Suppl 50 331
38 Le Jemtel T H, Padeletti M, Jelic S. Diagnostic and therapeutic challenges in patients with coexistent chronic obstructive pulmonary disease and chronic heart failure. J Am Coll Cardiol. 2007; 49 171-180
39 Wouters E F. Chronic obstructive pulmonary disease. 5: systemic effects of COPD. Thorax. 2002; 57 1067-1070
40 Agusti A G, Sauleda J, Miralles C. et al . Skeletal muscle apoptosis and weight loss in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2002; 166 485-489
41 Richardson R S, Leek B T, Gavin T P. et al . Reduced mechanical efficiency in chronic obstructive pulmonary disease but normal peak VO2 with small muscle mass exercise. Am J Respir Crit Care Med. 2004; 169 89-96
42 Guttridge D C, Mayo M W, Madrid L V. et al . NF-kappaB-induced loss of MyoD messenger RNA: possible role in muscle decay and cachexia. Science. 2000; 289 2363-2366
43 Vogiatzis I, Stratakos G, Simoes D C. et al . Effects of rehabilitative exercise on peripheral muscle TNFalpha, IL-6, IGF-I and MyoD expression in patients with COPD. Thorax. 2007; 62 950-956
44 Vandenbergh E, Van de Woestijne K P, Gyselen A. Weight changes in the terminal stages of chronic obstructive pulmonary disease. Relation to respiratory function and prognosis. Am Rev Respir Dis. 1967; 95 556-566
45 Landbo C, Prescott E, Lange P. et al . Prognostic value of nutritional status in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1999; 160 1856-1861
46 Donahoe M, Rogers R M, Wilson D O, Pennock B E. Oxygen consumption of the respiratory muscles in normal and in malnourished patients with chronic obstructive pulmonary disease. Am Rev Respir Dis. 1989; 140 385-391
47 Marquis K, Debigare R, Lacasse Y. et al . Midthigh muscle cross-sectional area is a better predictor of mortality than body mass index in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2002; 166 809-813
48 Bernard S, LeBlanc P, Whittom F. et al . Peripheral muscle weakness in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1998; 158 629-634
49 Pitta F, Troosters T, Spruit M A. et al . Characteristics of physical activities in daily life in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2005; 171 972-977
50 Schols A M, Slangen J, Volovics L, Wouters E F. Weight loss is a reversible factor in the prognosis of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1998; 157 1791-1797
51 Schols A M, Wouters E F. Nutritional abnormalities and supplementation in chronic obstructive pulmonary disease. Clin Chest Med. 2000; 21 753-762
52 Creutzberg E C, Schols A MWJ, Weling-Schepers C APM. et al . Characterization of nonresponse to high caloric oral nutritional therapy in depleted patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2000; 161 745-752
53 Bernard S, Whittom F, LeBlanc P. et al . Aerobic and strength training in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1999; 159 896-901
54 Sala E, Roca J, Marrades R M. et al . Effects of endurance training on skeletal muscle bioenergetics in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1999; 159 1726-1734
55 Schols A M, Soeters P B, Mostert R. et al . Physiologic effects of nutritional support and anabolic steroids in patients with chronic obstructive pulmonary disease. A placebo-controlled randomized trial. Am J Respir Crit Care Med. 1995; 152 1268-1274
56 Burdet L, de Muralt B, Schutz Y. et al . Administration of growth hormone to underweight patients with chronic obstructive pulmonary disease. A prospective, randomized, controlled study. Am J Respir Crit Care Med. 1997; 156 1800-1806
57 Anker S D, John M, Pedersen P U. et al . ESPEN Guidelines on Enteral Nutrition: Cardiology and pulmonology. Clin Nutr. 2006; 25 311-318
58 Snell N, Newbold P. The clinical utility of biomarkers in asthma and COPD. Curr Opin Pharmacol. 2008; 8 222-235
59 Sin D D, Man S F. Systemic inflammation and mortality in chronic obstructive pulmonary disease. Can J Physiol Pharmacol. 2007; 85 141-147
60 Sarir H, Henricks P A, van Houwelingen A H. et al . Cells, mediators and Toll-like receptors in COPD. Eur J Pharmacol. 2008; 585 346-353
61 Sin D D, Man S F, Marciniuk D D. et al . The effects of fluticasone with or without salmeterol on systemic biomarkers of inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2008; 177 1207-1214
62 Beeh K M, Kornmann O, Buhl R. et al . Neutrophil chemotactic activity of sputum from patients with COPD: role of interleukin 8 and leukotriene B4. Chest. 2003; 123 1240-1247
63 D’Silva L, Cook R J, Allen C J. et al . Changing pattern of sputum cell counts during successive exacerbations of airway disease. Respir Med. 2007; 101 2217-2220
64 Groenewegen K H, Postma D S, Hop W C. et al . Increased systemic inflammation is a risk factor for COPD exacerbations. Chest. 2008; 133 350-357
65 Traves S L, Culpitt S V, Russell R E. et al . Increased levels of the chemokines GROalpha and MCP-1 in sputum samples from patients with COPD. Thorax. 2002; 57 590-595
66 Gibson P G, Fujimura M, Niimi A. Eosinophilic bronchitis: clinical manifestations and implications for treatment. Thorax. 2002; 57 178-182
67 Pizzichini E, Pizzichini M M, Gibson P. et al . Sputum eosinophilia predicts benefit from prednisone in smokers with chronic obstructive bronchitis. Am J Respir Crit Care Med. 1998; 158 1511-1517
68 Hollander C, Sitkauskiene B, Sakalauskas R. et al . Serum and bronchial lavage fluid concentrations of IL-8, SLPI, sCD14 and sICAM-1 in patients with COPD and asthma. Respir Med. 2007; 101 1947-1953
69 Gillissen A, Bartling A, Rasche K. Bronchoalveoläre Lavage. Klinikarzt. 1997; 26 50-56
70 Dalaveris E, Kerenidi T, Katsabeki-Katsafli A. et al . VEGF, TNF-alpha and 8-isoprostane levels in exhaled breath condensate and serum of patients with lung cancer. Lung Cancer. 2009; 64 219-225
71 Kharitonov S A, Barnes P J. Exhaled biomarkers. Chest. 2006; 130 1541-1546
72 Nowak D, Kasielski M, Antczak A. et al . Increased content of thiobarbituric acid-reactive substances and hydrogen peroxide in the expired breath condensate of patients with stable chronic obstructive pulmonary disease: no significant effect of cigarette smoking. Respir Med. 1999; 93 389-396
73 Jorres R A. Modelling the production of nitric oxide within the human airways. Eur Respir J. 2000; 16 555-560
74 Kharitonov S A, Barnes P J. Clinical aspects of exhaled nitric oxide. Eur Respir J. 2000; 16 781-792
75 Vestbo J, Anderson W, Coxson H O. et al . Evaluation of COPD Longitudinally to Identify Predictive Surrogate End-points (ECLIPSE). Eur Respir J. 2008; 31 869-873
76 Donaldson G C, Seemungal T A, Patel I S. et al . Airway and systemic inflammation and decline in lung function in patients with COPD. Chest. 2005; 128 1995-2004
77 Dahl M, Vestbo J, Lange P. et al . C-reactive protein as a predictor of prognosis in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2007; 175 250-255
78 Wouters E F, Groenewegen K H, Dentener M A, Vernooy J H. Systemic inflammation in chronic obstructive pulmonary disease: the role of exacerbations. Proc Am Thorac Soc. 2007; 4 626-634
79 Culpitt S V, Maziak W, Loukidis S. et al . Effect of high dose inhaled steroid on cells, cytokines, and proteases in induced sputum in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1999; 160 1635-1639
80 Loppow D, Schleiss M B, Kanniess F. et al . In patients with chronic bronchitis a four week trial with inhaled steroids does not attenuate airway inflammation. Respir Med. 2001; 95 115-121
81 Barnes N C, Qiu Y S, Pavord I D. et al . Antiinflammatory effects of salmeterol/fluticasone propionate in chronic obstructive lung disease. Am J Respir Crit Care Med. 2006; 173 736-743
82 Sin D D, Lacy P, York E, Man S F. Effects of fluticasone on systemic markers of inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2004; 170 760-765
83 Pinto-Plata V M, Mullerova H, Toso J F. et al . C-reactive protein in patients with COPD, control smokers and non-smokers. Thorax. 2006; 61 23-28
84 Donaldson G C, Seemungal T A, Bhowmik A, Wedzicha J A. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax. 2002; 57 847-852
85 Burgel P R, Nesme-Meyer P, Chanez P. et al . Cough and sputum production are associated with frequent exacerbations and hospitalization in COPD. Chest. 2009; 135 975-982
86 Celli B R, Barnes P J. Exacerbations of chronic obstructive pulmonary disease. Eur Respir J. 2007; 29 1224-1238
87 Saetta M, di SA , Maestrelli P. et al . Airway eosinophilia in chronic bronchitis during exacerbations. Am J Respir Crit Care Med. 1994; 150 1646-1652
88 Sethi S. Infectious etiology of acute exacerbations of chronic bronchitis. Chest. 2000; 117 380S-385S
89 Hurst J R, Perera W R, Wilkinson T M. et al . Systemic and upper and lower airway inflammation at exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2006; 173 71-78
90 Rohde G, Borg I, Wiethege A. et al . Inflammatory response in acute viral exacerbations of COPD. Infection. 2008; 36 427-433
91 Pinto-Plata V M, Livnat G, Girish M. et al . Systemic cytokines, clinical and physiological changes in patients hospitalized for exacerbation of COPD. Chest. 2007; 131 37-43
92 Perera W R, Hurst J R, Wilkinson T M. et al . Inflammatory changes, recovery and recurrence at COPD exacerbation. Eur Respir J. 2007; 29 527-534
93 Bourne S, Fingleton J. Brain natriuretic peptide (BNP) levels during acute exacerbations of COPD – a novel biomarker. Eur Respir J. 2008; 32 401
94 Tashkin D, Decramer M, Mannino D. et al . Elevated incidence of serious non-respiratory adverse events following COPD exacerbations in clinical trials. American Journal of Respiratory and Critical Care Medicine. 2008; 177 A132
95 Washko G R, Fan V S, Ramsey S D. et al . The effect of lung volume reduction surgery on chronic obstructive pulmonary disease exacerbations. Am J Respir Crit Care Med. 2008; 177 164-169
96 Kasahara Y, Tuder R M, Taraseviciene-Stewart L. et al . Inhibition of VEGF receptors causes lung cell apoptosis and emphysema. J Clin Invest. 2000; 106 1311-1319
97 Kasahara Y, Tuder R M, Cool C D. et al . Endothelial cell death and decreased expression of vascular endothelial growth factor and vascular endothelial growth factor receptor 2 in emphysema. Am J Respir Crit Care Med. 2001; 163 737-744
98 Crookshank A D, Travaline J M, Ciccolella D E. et al . Endothelial dysfunction in acute exacerbations of COPD and at baseline. Am J Respir Crit Care Med. 2007; 175 A514
99 Lee S H, Goswami S, Grudo A. et al . Antielastin autoimmunity in tobacco smoking-induced emphysema. Nat Med. 2007; 13 567-569
100 Frey U, Suki B. Complexity of chronic asthma and chronic obstructive pulmonary disease: implications for risk assessment, and disease progression and control. Lancet. 2008; 372 1088-1099
101 Mapel D W, Dedrick D, Davis K. Trends and cardiovascular co-morbidities of COPD patients in the Veterans Administration Medical System, 1991 – 1999. COPD. 2005; 2 35-41
102 Sheifer S E, Rathore S S, Gersh B J. et al . Time to presentation with acute myocardial infarction in the elderly: associations with race, sex, and socioeconomic characteristics. Circulation. 2000; 102 1651-1656
103 Holguin F, Folch E, Redd S C, Mannino D M. Comorbidity and mortality in COPD-related hospitalizations in the United States, 1979 to 2001. Chest. 2005; 128 2005-2011
104 Scharf S M, Iqbal M, Keller C. et al . Hemodynamic characterization of patients with severe emphysema. Am J Respir Crit Care Med. 2002; 166 314-322
105 Rutten F H, Cramer M J, Zuithoff N P. et al . Comparison of B-type natriuretic peptide assays for identifying heart failure in stable elderly patients with a clinical diagnosis of chronic obstructive pulmonary disease. Eur J Heart Fail. 2007; 9 651-659
106 Sin D D, Man S F. Why are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular diseases? The potential role of systemic inflammation in chronic obstructive pulmonary disease. Circulation. 2003; 107 1514-1519
107 Zacho J, Tybjaerg-Hansen A, Jensen J S. et al . Genetically elevated C-reactive protein and ischemic vascular disease. N Engl J Med. 2008; 359 1897-1908
108 Salpeter S R, Ormiston T M, Salpeter E E. Cardiovascular effects of beta-agonists in patients with asthma and COPD: a meta-analysis. Chest. 2004; 125 2309-2321
109 Lee T A, Pickard A S, Au D H. et al . Risk for death associated with medications for recently diagnosed chronic obstructive pulmonary disease. Ann Intern Med. 2008; 149 380-390
110 Singh S, Loke Y K, Furberg C D. Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. JAMA. 2008; 300 1439-1450
111 Tashkin D P, Celli B, Senn S. et al . A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med. 2008; 359 1543-1554
112 Chen J, Radford M J, Wang Y. et al . Effectiveness of beta-blocker therapy after acute myocardial infarction in elderly patients with chronic obstructive pulmonary disease or asthma. J Am Coll Cardiol. 2001; 37 1950-1956
113 Dransfield M T, Rowe S M, Johnson J E. et al . Use of beta blockers and the risk of death in hospitalised patients with acute exacerbations of COPD. Thorax. 2008; 63 301-305
114 Mancini G B, Etminan M, Zhang B. et al . Reduction of morbidity and mortality by statins, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers in patients with chronic obstructive pulmonary disease. J Am Coll Cardiol. 2006; 47 2554-2560
115 Sidney S, Sorel M, Quesenberry Jr. C P. et al . COPD and incident cardiovascular disease hospitalizations and mortality: Kaiser Permanente Medical Care Program. Chest. 2005; 128 2068-2075
116 Mannino D M, Thorn D, Swensen A, Holguin F. Prevalence and outcomes of diabetes, hypertension and cardiovascular disease in COPD. Eur Respir J. 2008; 32 962-969
117 Ozge C, Ozge A, Yilmaz A. et al . Cranial optic nerve involvements in patients with severe COPD. Respirology. 2005; 10 666-672
118 Jann S, Gatti A, Crespi S. et al . Peripheral neuropathy in chronic respiratory insufficiency. J Peripher Nerv Syst. 1998; 3 69-74
119 Di Marco F, Verga M, Reggente M. et al . Anxiety and depression in COPD patients: The roles of gender and disease severity. Respiratory Medicine. 2008; 100 1767-1774
120 Almagro P, Calbo E, Ochoa d E. et al . Mortality after hospitalization for COPD. Chest. 2002; 121 1441-1448
121 Gudmundsson G, Gislason T, Lindberg E. et al . Mortality in COPD patients discharged from hospital: the role of treatment and co-morbidity. Respir Res. 2006; 7 109
122 Lee T A, Shields A E, Vogeli C. et al . Mortality rate in veterans with multiple chronic conditions. J Gen Intern Med. 2007; 22 Suppl 3 403-407
123 Steinkamp G, Dierkesmann R, Gillissen A. et al . COPD und Psyche – ein Überblick. Pneumologie. 2005; 59 819-830

Prof. Dr. G. Schultze-Werninghaus

Berufsgenossenschaftliches Universitätsklinikum Bergmannsheil GmbH
Medizinische Klinik III – Pneumologie, Allergologie, Schlaf- und Beatmungsmedizin

Bürkle-de-la-Camp-Platz 1
44789 Bochum

Email: gerhard.schultze-werninghaus@bergmannsheil.de